Short Call at News Buzzer: AbbVie Inc. (NYSE:ABBV), QUALCOMM Incorporated (NASDAQ:QCOM)

AbbVie Inc. (NYSE:ABBV) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with -0.62% to $60.58. AbbVie (ABBV) reported that its marketing authorization application or MAA has been validated. It is now under accelerated assessment by the European Medicines Agency or EMA for the company’s investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) for the treatment of all major chronic hepatitis C virus (HCV) genotypes. If authorized, G/P may provide a shorter treatment duration for genotypes 1-6 (GT1-6) patients without cirrhosis, who make up the majority of HCV patients, and an additional treatment option to patients with compensated cirrhosis (Child-Pugh A).G/P is also intended to address the needs of patients with specific treatment challenges, including those with severe chronic kidney disease (CKD) and those not cured with previous direct-acting antiviral (DAA) treatment. The share price of ABBV attracts active investors, as stock price of week volatility recorded 1.36%. The stock is going forward to its 52-week low with 21.89% and lagging behind from its 52-week high price with -9.34%.

QUALCOMM Incorporated (NASDAQ:QCOM) [Trend Analysis] surged reacts as active mover, shares an advance 0.22% to traded at $55.00 and the percentage gap between open changing to regular change was 0.26%. Lundin Law PC, a shareholder rights firm announces a class action lawsuit against QUALCOMM Incorporated (QCOM) concerning possible violations of federal securities laws. Investors who purchased or otherwise acquired QUALCOMM shares between February 1, 2012 and January 17, 2017 inclusive, are encouraged to contact the firm prior to March 24, 2017, also known as the lead plaintiff motion deadline.

On January 17, 2017, Bloomberg revealed that U.S. antitrust officials were organizing a lawsuit against QUALCOMM for allegedly engaging in unfair practices and gaining a monopoly over the processing chips used in cellphones.These claims regard licensing contracts between QUALCOMM and Apple, Inc. to only provide chips for Apple, Inc. phones. The firm’s current ratio calculated as 3.10 for the most recent quarter. The firm past twelve months price to sales ratio was 3.53 and price to cash ratio remained 4.46. As far as the returns are concern, the return on equity was recorded as 18.70% and return on investment was 11.90% while its return on asset stayed at 11.20%. The firm has total debt to equity ratio measured as 0.37.

 

About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *